Two Leading Labs Confirm RHB-204 MAP-Killing Effect for RedHill's Crohn's Disease Candidate

What To Know

Two independent in vitro microbiology studies reported here found that RedHill’s investigational oral formulation RHB‑204 kills Mycobacterium avium subspecies paratuberculosis (MAP) and showed MAP‑killing comparability to the company’s earlier RHB‑104 formulation.

The article is a company press release summarizing lab results and referencing prior positive Phase 3 data for RHB‑104; it frames RHB‑204 as a Phase‑2‑ready, next‑generation MAP‑targeted candidate intended for MAP‑positive Crohn’s disease patients.

These results are laboratory (in vitro) findings across multiple MAP strains using long‑term intracellular culture and spot/phage assays. The release emphasizes potential for lower doses of two active ingredients in RHB‑204 versus RHB‑104 and suggests reduced toxicity and enhanced adherence, but it does not present clinical trial data for RHB‑204 itself.

The company also notes collaborations on MAP detection diagnostics that could support future MAP‑targeted clinical trials. This is a company PR (press release) describing preclinical lab work; it should be viewed as early-stage evidence that requires independent peer‑review and clinical testing in MAP‑positive patients before clinical implications are known.